Dr. Goldlust, who practices in Hackensack, N.J., has been recognized by the End Brain Cancer Initiative for his compassion and his dedication to brain tumor patients. Cancers and their treatments can cause neurologic symptoms, such as seizures, stroke, neuropathy and cognitive effects — even without directly invading the nervous system. Dr. Goldlust is a neuro-oncologist who specializes in the treatment of brain tumors and the neurological issues that arise from multimodality cancer therapies. With neurosurgeon George Kaptain, MD, he founded the Brain and Spine Institute at John Theurer Cancer Center. He has helped bring JTCC to the forefront of brain tumor clinical care and research, having served as principal investigator on 25 studies of novel therapeutics, primarily for glioblastoma, and several as the national lead investigator. He is widely published in the neuro-oncology medical literature, including recent practice-changing contributions to “Lancet Oncology,” “Neuro-Oncology” and the “Journal of Clinical Oncology.” He serves as the JTCC lead investigator for ALLIANCE (the National Cancer Institute’s premier clinical trial collaborative) and on the Clinical Research Committee of Georgetown Lombardi Comprehensive Cancer Center
New York University Hospital, residency in neurology, served as chief resident
Memorial Sloan Cancer Center, fellowship, under mentorship of Dr. Jerome Posner, in neurological oncology; elected to serve as chief fellow in final year of training
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.
